Shanghai Medicilon Inc. (SHA:688202)
China · Delayed Price · Currency is CNY 107.64
+3.68 (3.54%)
At close: Sep 30, 2026
Shanghai Medicilon Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,160 | 7,419 | 4,033 | 9,209 | 18,612 | 30,145 | |
Market Cap Growth | 62.52% | 83.97% | -56.21% | -50.52% | -38.26% | 209.24% |
Enterprise Value | 13,828 | 7,211 | 3,664 | 8,561 | 18,568 | 29,822 |
Last Close Price | 107.64 | 56.40 | 30.17 | 68.38 | 152.34 | 246.15 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 55.03 | 106.81 |
Forward PE | - | 18.74 | 17.14 | 44.40 | 100.83 | 100.83 |
PS Ratio | 10.23 | 6.38 | 3.89 | 6.74 | 11.22 | 25.83 |
PB Ratio | 7.07 | 3.84 | 1.88 | 3.67 | 11.61 | 22.71 |
P/TBV Ratio | 8.15 | 4.46 | 2.17 | 4.14 | 14.22 | 27.51 |
P/FCF Ratio | 795.77 | 205.29 | - | - | - | 188.15 |
P/OCF Ratio | 85.66 | 70.54 | - | 276.39 | - | 66.56 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 9.99 | 6.20 | 3.53 | 6.27 | 11.19 | 25.55 |
EV/EBITDA Ratio | - | - | - | 6304.74 | 48.34 | 84.13 |
EV/EBIT Ratio | - | - | - | - | 57.56 | 96.68 |
EV/FCF Ratio | 777.11 | 199.54 | - | - | - | 186.13 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.11 | 0.13 | 0.16 | 0.15 | 0.17 | 0.03 |
Debt / EBITDA Ratio | 220.55 | - | - | 19.65 | 0.68 | 0.12 |
Debt / FCF Ratio | 12.52 | 6.85 | - | - | - | 0.27 |
Net Debt / Equity Ratio | -0.17 | -0.16 | -0.17 | -0.24 | 0.05 | -0.35 |
Net Debt / EBITDA Ratio | 23.73 | 3.41 | 1.27 | -447.19 | 0.20 | -1.32 |
Net Debt / FCF Ratio | -18.66 | -8.84 | 2.66 | 3.99 | -0.18 | -2.93 |
Asset Turnover | 0.48 | 0.43 | 0.34 | 0.49 | 0.81 | 0.74 |
Inventory Turnover | 7.48 | 8.96 | 7.47 | 6.30 | 7.73 | 11.01 |
Quick Ratio | 1.35 | 1.79 | 2.29 | 2.43 | 1.26 | 1.99 |
Current Ratio | 1.84 | 2.11 | 2.49 | 2.73 | 1.74 | 2.33 |
Return on Equity (ROE) | -5.06% | -8.24% | -14.23% | -1.62% | 23.09% | 23.11% |
Return on Assets (ROA) | -2.33% | -4.24% | -7.63% | -1.88% | 9.78% | 12.21% |
Return on Invested Capital (ROIC) | -6.35% | -10.87% | -20.16% | -4.70% | 23.35% | 35.58% |
Return on Capital Employed (ROCE) | -5.10% | -9.00% | -16.50% | -3.30% | 18.80% | 21.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.73% | -2.26% | -8.20% | -0.36% | 1.82% | 0.94% |
FCF Yield | 0.13% | 0.49% | -3.30% | -1.65% | -2.29% | 0.53% |
Dividend Yield | - | - | - | - | 0.18% | 0.28% |
Payout Ratio | - | - | - | - | 25.82% | 13.84% |
Buyback Yield / Dilution | -2.22% | 1.34% | -4.86% | -4.98% | -0.08% | -0.19% |
Total Shareholder Return | -2.22% | 1.34% | -4.86% | -4.98% | 0.11% | 0.09% |